Novavax, Inc. (NVAX) Produces MERS-CoV Vaccine Candidate  
6/6/2013 9:24:59 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md., June 6, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it had successfully produced a vaccine candidate designed to provide protection against the recently emerging Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The vaccine candidate, which was made using Novavax' recombinant nanoparticle vaccine technology, is based on the major surface spike (S) protein. The Company believes that its MERS-CoV vaccine candidate may provide a path forward for a vaccine for this emerging threat.

Help employers find you! Check out all the jobs and post your resume.